Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Date:2/6/2009

d for the treatment of schizophrenia in the E.U. If approved, Janssen will also market paliperidone palmitate.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a subsidiary of Johnson & Johnson, the world's most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com.

Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is based in Titusville, N.J. and is the only large pharmaceutical company in the U.S. dedicated solely to mental health. It currently markets prescription medications for the treatment of schizophrenia, bipolar mania and the treatment of symptoms associated with autistic disorder. For more information about Janssen, visit http://www.janssen.com.

IMPORTANT SAFETY INFORMATION FOR INVEGA

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with paliperidone and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

One ri
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Atossa Genetics, Inc. (NASDAQ: ATOS ), The Breast ... , Chief Financial Officer & General Counsel, will present at ... 30, 2013, in New York City ... presentation is scheduled to begin at 3:30 p.m. EDT and ... webcast, go to www.atossagenetics.com . For more ...
(Date:5/17/2013)... , May 17, 2013 Oramed ... of oral drug delivery systems, announced today that the ... the Company,s Investigational New Drug application(IND) for ORMD-0801, its ... to have the FDA clearance to proceed," stated ... upcoming trial is a major milestone for Oramed and ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
(Date:5/18/2013)... Just a few extra cups of coffee each month ... disease known as primary sclerosing cholangitis (PSC), a new ... Rochester, Minn., found that drinking coffee was associated with ... lead to cirrhosis of the liver, liver failure and ... cause-and-effect relationship. "While rare, PSC has extremely ...
(Date:5/18/2013)... coffee is associated with a reduced risk of ... Mayo Clinic research shows. The findings were being ... in Orlando, Fla. , PSC is an ... in inflammation and subsequent fibrosis that can lead ... biliary cancer. , "While rare, PSC has extremely ...
(Date:5/18/2013)... City, Utah (PRWEB) May 18, 2013 ... information on insurance agents’ role in Marketplaces ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... of Health and Human Services (HHS) recently released ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 As ... courts throughout the country, Bernstein Liebhard LLP notes that ... patients often suffer tissue damage before they experience any ... according to Science Daily will appear in the Journal ... recipients underwent MRI screens of their hips. The ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... Computers still are considered to be a high tech machine ... manufacturers are working hard to make it otherwise//. There is ... of despair and confusion. Dr J?rg Voskamp, from Germany's Fraunhofer ... to read one’s emotions. A sensitive PC is a research ...
... treatment of different types of cancer. The Beatson Oncology cancer centre ... about 39 people over// a period of 20 years. But only ... the overdose in the case of a 15 year old teenager. ... a lot of pain and burned her skin. She had to ...
... Australian model says that she had a lot of insecurities as ... "amazing body" //. ,Macpherson hated her tall figure because she ... have to say I had an amazing body and I didn't ... so Amazonian and it wasn't really fashionable at the time. I ...
... by the experts to concentrate on organic farming in order ... alarmingly dropping due to the use of chemical fertilizer. // ... who have just ended their field trip to the hill ... farming. ,Apple is the main cash crop of ...
... a survey that found that almost 80 percent of Shanghai ... ,Yu Junde, coordinator of Survey and head official of ... improper wearing of bras which could affect their health. ... of 18 to 50, which revealed that many were wearing ...
... that an individual’s race plays a crucial role in determining ... background (one Black and one white parent) // to think ... about their Black parent, they were able to spot the ... same speed and accuracy as a monoracial Black individual. The ...
Cached Medicine News:Health News:Organic Farming May Increase The Output Of Apples In Himachal 2Health News:Shanghai Women Don their Bras Improperly 2
Flag shaped sharp tip. Flat serrated handle with polished finish....
For use with E0828 A needle tip and E0828 B gouge tip. Round knurled with threaded ended for tips. Most popular size or model....
Threaded ends permit guarding the needle and gouge within the handle. Set consists of one each : E0828 A needle tip, E0828 B gauge tip and E0828 C handle. Most popular size or model....
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
Medicine Products: